Ardelyx Stock News

Shares of Ardelyx Inc. undefined soared 27.2% on massive volume in midday trading Wednesday, and have now nearly doubled in two days since the company

Ardelyx, Inc. (NASDAQ: ARDX) has reported plans to launch IBSRELA, the approved treatment for irritable bowel syndrome with constipation (IBS-C) in adults in the second quarter of 2022. Mike Raab, president and chief executive officer of Ardelyx, stated, Over the last five years, the IBS-C market has grown to be sizeable and concentrated, with 9,000 high-writing physicians The post Ardelyx Plans to Launch IBSRELA to Treat IBS-C in Q2 2022 first appeared on Financial Buzz .

Futures Surge After Powell-Driven Rout Proves To Be "Transitory" Heading into yesterday''s painful close to one of the ugliest months since March 2020, which saw a huge forced liquidation rebalance with more than $8 billion in Market on Close orders, we said that while we are seeing "forced selling dump into the close today" this would be followed by "forced Dec 1 buying frontrunning after the close." Forced selling dump into the close today. Forced Dec 1 buying frontrunning after the close zerohedge (@zerohedge) November 30, 2021 And just as expected, despite yesterday''s dramatic hawkish pivot by Powell, who said it was time to retire the word transitory in describing the inflation outlook (the same word the Fed used hundreds of times earlier in 2021 sparking relentless mockery from this website for being clueless as usual) while also saying the U.S. central bank would consider bringing forward plans for tapering its bond buying program at its next meeting in two weeks, the frontrunning of new monthly inflows is in full force with S&P futures rising over 1.2%, Nasdaq futures up 1.3%, and Dow futures up 0.9%, recovering almost all of Tuesdays decline.

Citigroup raised the price target on Ardelyx Inc (NASDAQ: ARDX ) to $13 from $7, with a Buy rating unchanged. The update follows the Company''s plans to launch Ibsrela (tenapanor) for irritable bowel syndrome with constipation (IBS-C) independently in Q2 2022. Analyst Yigal Nochomovitz added IBS-C revenues in the U.S. back to his model and noted that his estimates are in line with management''s guidance for $500M at peak, which Nochomovitz sees coming in 2029. He also argues that the Ibsrela Full story available on Benzinga.com

This article was originally published on TipRanks.com Ardelyx, Inc. The post Ardelyx to Launch IBSRELA in 2022; Shares Pop appeared first on Smarter Analyst .

Shares of Ardelyx Inc. ARDX, +24.56% soared 27.2% on massive volume in midday trading Wednesday, and have now nearly doubled in two days since the company announced plans to launch its treatment for i

Ardelyx (ARDX) stock is soaring higher on Wednesday following an update concerning the company's ISB-C treatment in adults. The post ARDX Stock Alert: The IBS Drug News Sending Ardelyx Shares Soaring

Citigroup raised the price target on Ardelyx Inc (NASDAQ:ARDX) to $13 from $7, with a Buy rating unchanged. The update follows the Company's plans to launch Ibsrela (tenapanor) for irritable bow

Ardelyx, Inc. (NASDAQ:ARDX) saw some unusual options trading activity on Tuesday. Stock investors bought 16,175 call options on the stock. This represents an increase of approximately 970% compared to the typical daily volume of 1,512 call options. Shares of NASDAQ:ARDX traded up $0.28 during midday trading on Tuesday, reaching $1.14. 47,356,225 shares of the company []

Ardelyx Inc. (NASDAQ:ARDX) traded at $0.86 at last check on Tuesday, November 30, made a downward move of -0.59% on its previous days price. Looking at the stock we see that its previous close was $0.86 and the beta (5Y monthly) reads 1.84 with the days price range being $0.862 $0.91. In terms of Before You Invest, Make Sure You Check This Ardelyx Inc. (NASDAQ: ARDX) Analysis Read More »

The stock price of Ardelyx Inc (NASDAQ: ARDX) increased by over 24% during intraday trading today. This is why it happened.

Ardelyx Inc (ARDX) shares closed today at just slightly above its 52 week low of $0.86, giving the company a market cap of $97M. The stock is currently down 86.7% year-to-date, down 86.3% over the past 12 months, and down 94.6% over the past five years. This week, the Dow Jones Industrial Average fell 1.4%, and the S&P 500 fell 0.6%. Trading Activity Trading volume this week was 39.4% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -1470.0% The company's stock price performance over the past 12 months lags the peer average by -2214.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Ardelyx, Inc. (ARDX) with the stream of -3.41% also noticed, India Oyster Point Pharma, Inc. (OYST) encountered a rapid change of -2.37% in the last hour of Mondays trading session. The post Beholding Stock: Ardelyx, Inc. (NASDAQ:ARDX), Oyster Point Pharma, Inc. (NASDAQ:OYST) appeared first on Stocks Equity .

Charles Schwab Investment Management Inc. lessened its holdings in shares of Ardelyx, Inc. (NASDAQ:ARDX) by 13.5% during the 2nd quarter, HoldingsChannel reports. The firm owned 209,012 shares of the biopharmaceutical companys stock after selling 32,685 shares during the period. Charles Schwab Investment Management Inc.s holdings in Ardelyx were worth $1,585,000 at the end of the []